videoDetails)

COVID-19 Vaccine: India’s COVAXIN gets DCGI approval for human clinical trials
)
The Drug Controller General of India has allowed Bharat Biotech India (BBIL) to conduct human clinical trials for ‘COVAXIN’, a potential COVID-19 vaccine. The human clinical trials will start across India in July 2020. If it emerges successful, COVAXIN will be available by year’s end.